Introduction of New Lupus Nephritis Guidelines

The 2024 American College of Rheumatology Lupus Nephritis Guidelines mark a significant update after a decade, incorporating advancements in therapies and a more holistic approach to patient management. The guidelines now reflect new FDA-approved treatments such as bulimumab and voclosporin, which demonstrate improved outcomes for lupus nephritis patients compared to outdated recommendations from 2012. Key outcomes from recent clinical studies have informed this update, underscoring the importance of integrating these innovative therapies into treatment plans. By acknowledging these changes, the new guidelines position healthcare providers to make more informed decisions about lupus nephritis management in clinical practice.